Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas.
Yomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu...
https://pubmed.ncbi.nlm.nih.gov/39908567/Actively Recruiting
Led by Baylor College of Medicine · Updated on 2026-03-02
136
Participants Needed
3
Research Sites
17 weeks
Total Duration
This research aims to evaluate the use of specially trained immune cells called GRALE T cells for patients with certain types of lymph gland diseases, including Hodgkins Disease, Non-Hodgkins Lymphoma, TNK-lymphoproliferative disease, or severe chronic active Epstein Barr Virus CAEBV. These diseases either have returned, are at risk of returning, or have not responded to previous treatments. The study focuses on patients whose tumors show the Epstein Barr virus, which can hide from the immune system and may contribute to these cancers. Researchers want to see if GRALE T cells can survive in the blood and impact the tumor. Participants or their donors will provide blood to grow EBV-specific GRALE T cells in the lab. Some patients may receive chemotherapy drugs cyclophosphamide and fludarabine to prepare their blood for the T cells. The GRALE T cells will be thawed and infused into patients over a few minutes, with two doses given two weeks apart. If there is a partial response or stable disease after these doses, patients may receive up to six additional infusions. Treatments are given at specialized centers, and patients may or may not receive chemotherapy to help the T cells grow. Throughout the study, participants will have scans and blood tests to assess tumor size and immune response. After infusions, patients will be followed regularlyevery three months for a year, then yearly for up to five yearsto monitor safety and effectiveness. The main outcome is to determine the highest safe dose of these T cells and observe side effects. Researchers will also study how well the T cells survive and their anti-viral and anti-tumor effects over one year.
CONDITIONS
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
H
Helen E Heslop, MD
V
Vicky Torrano
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Baylor College of Medicine
Lead Sponsor
The Methodist Hospital Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | EBV‑specific cytotoxic T cells (investigational) | Standard R‑CHOP chemotherapy (contextual) |
|---|---|---|
| What it is | An investigational cellular therapy using EBV‑specific cytotoxic T lymphocytes generated at Dose Level 3 (1 × 10^8 cells/m² plus 2 × 10^8 cells/m²) | Established chemo‑immunotherapy regimen such as R‑CHOP combining rituximab with CHOP chemotherapy |
| Role in trial | Single‑group investigational treatment evaluated for safety, toxicity and immune activity | Not part of this study; used as external comparison |
| Primary use | To treat relapsed or refractory EBV‑positive lymphomas by targeting viral antigens via T cells | To eradicate EBV‑positive lymphoma using immunochemotherapy targeting B cells and lymphoma cells |
| How it is given | Patients receive EBV‑specific T cell infusion, with or without prior lymphodepletion, at defined dose levels | Given as intravenous chemotherapy plus monoclonal antibody on an outpatient schedule over cycles |
| Evidence status | Limited evidence from early‑phase trial; efficacy and survival outcomes not yet established | Strong long‑term evidence supports efficacy in aggressive lymphomas with known survival benefit |
| Important risks | Safety profile not yet fully known; potential for infusion‑related or immune‑mediated effects | Known risks of chemotherapy including cytopenias, infection and organ toxicity |
| Important limitations | Single‑group early‑phase design, small numbers, no comparator arm, unknown long‑term outcomes | Substantial toxicity and reduced efficacy in relapsed or refractory EBV‑positive cases |
| Patient impact | Not yet measurable in terms of patient‑relevant outcomes | Established improvements in survival and remission for many patients with aggressive lymphoma |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 4 weeks
Participants receive two infusions of EBV-specific cytotoxic T-lymphocytes 14 days apart. Some participants may receive chemotherapy drugs cyclophosphamide and fludarabine intravenously daily for three days before the T-cell infusions to prepare the body.
2 infusions 2 weeks apart; chemotherapy given daily over 3 days if applicable
Duration - Up to 5 years after last infusion
Participants are followed up with clinic visits or yearly contacts by a research nurse for up to 5 years after the last infusion to monitor health and response to treatment. For those receiving additional infusions, follow-up occurs every 3 months until 12 months after the last infusion, then yearly thereafter.
Clinic visits or yearly contacts; every 3 months follow-up for 1 year after additional infusions
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu...
https://pubmed.ncbi.nlm.nih.gov/39908567/Sandhya Sharma, Naren U Mehta, Tim Sauer...
https://pubmed.ncbi.nlm.nih.gov/38640255/Baylor College of Medicine
Lead Sponsor
The Methodist Hospital Research Institute
Collaborating Sponsor